Polishing up Pearl

Existing VCs invested $65 million more in Pearl Therapeutics Inc. to support Phase III testing of its lead chronic obstructive pulmonary disease compound, because they think PT003 will offer greater bronchodilation and more reliable dosing than more advanced products.